Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology reports 2023-12, Vol.50, p.101311, Article 101311
1. Verfasser: Rose, Peter G
Format: Artikel
Sprache:eng
Schlagworte:
Survey
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2023.101311